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ABSTRACT 
Tumor-associated tumor necrosis factor (TNF) production in patients as well as a 
TNF-inducing membrane constituent of tumor c e l l s have been reported. In a murine 
fibrosarcoma model we analyzed TNF production during growth of a tumor 
transplant. In situ hybridization showed that a gradually increasing number of 
c e l l s within the tumor tissue became positive for TNFmRNA. Also, i n spleen c e l l s 
of tumor-bearing mice TNFmRNA became more abundant i n later stages of tumor 
growth compared to early stages. In plasma of these animals, however, TNF 
a c t i v i t y was not detected at any time even after stimulation with bacterial 
endotoxin. Neutralization with monoclonal antibodies of endogenous TNF during 
tumor growth did not affect the growth rate of the tumor, indicating that either 
the antibodies did not reach the relevant TNF production and action s i t e s or that 
endogenously produced TNF did not play a significant role in t h i s tumor model. 
INTRODUCTION 
TNF i s a product mainly of activated monocytes/macrophages which besides i t s 
cytotoxic a c t i v i t y in vitro for some tumor c e l l s exerts a plethora of effects on 
many different kinds of c e l l types. Due to numerous b i o l o g i c a l l y important 
functions, TNF i s thought to play a key role in regulation of the nonspecific 
host response in inflammation. Monocytes of cancer patients have been shown to 
spontaneously release s i g n i f i c a n t l y higher amounts of TNF into the supernatant 
when compared to controls (1). Also, enhanced levels of TNF i n serum or plasma of 
cancer patients have been reported (2,3). In these patients, after resection of 
the tumors the TNF levels returned to that of controls (3). 
In addition, we were able to demonstrate that tumor membrane constituents 
d i r e c t l y activate human monocytes for TNF production (4). TNFmRNA expression by 
tumor i n f i l t r a t i n g macrophages has also been reported recently (5). In order to 
investigate whether TNF production correlates with tumor growth, we determined 
TNF i n plasma and TNFmRNA in tumors and spleens of mice inoculated intradermally 
with fibrosarcoma c e l l s . In addition, to address the question of the role of the 
observed tumor-induced TNF the animals were treated with anti-murine TNF 
monoclonal antibodies throughout the experiment. 
MATERIALS AND METHODS 
Tumor C e l l s : Methylcholanthrene-induced fibrosarcoma c e l l s CFS1 were generated on 
a C3H mouse and kept at the German Cancer Research Center. The c e l l s were grown 
as single c e l l s i n tissue culture in RPMI 1640 (Gibco) with 10% FCS. The c e l l s 
were washed i n phosphate buffered saline (PBS) and l x l O 6 CFS1 c e l l s in 50pi PBS 
were injected intradermally into the flanks of C3H mice (Staatl. 
Versuchstieranstalt, Hannover, F.R.6.). 
Northern Blot Analysis; Cytoplasmic RNA was prepared from the spleens of 
individual mice at different times during tumor growth, electrophoresed in 1% 
agarose-formaldehyde gels. RNA was transferred to nylon f i l t e r s and hybridized as 
previously described (4). A TNFcDNA probe (a 750 bp Eco Rl-fragment of the coding 
region of human TNFcDNA) was labeled with 3 2P by the random primer method. After 
autoradiography the f i l t e r s were stripped and hybridized with a human /?-actin 
cDNA probe (a 560 bp Sal 1-Eco RI fragment of /?-actin cDNA). The hybridization 
signals were quantified by scanning the optical density of the autoradiograms. 
The TNFmRNA signals were evaluated by normalization using the respective actin 
mRNA signals. 
In Situ Hybridization; Tumor tissue was frozen in l i q u i d nitrogen immediately 
after excision and kept at -70°C u n t i l the preparation of 5mm cryosections. 
Fixation and hybridization was performed as described recently (4). 
TNF Bioassav and ELISA; Blood was collected from the ret r o o r b i t a l plexus at 
indicated times. Plasma was prepared and stored at -20°C u n t i l tested for TNF 
ac t i v i t y i n the L929 bioassay (7) (in the presence of actinomycin D) and in a 
spe c i f i c ELISA for murine TNF. A monoclonal rat ant i murine TNF antibody was 
generated by immunization of rats with purified natural murine TNF and fusion of 
the spleens of these rats with P3.X63.Ag8.653. One clone (Vlq) was selected which 
neutralized murine TNF. lpg Vlq Ig neutralized 80 pg of recombinant murine TNF 
(rmTNF, Knoll AG, Ludwigshafen, FRG). In vivo, 20 pg Vlq given i p were able to 
protect mice from LPS-induced lethal shock (Echtenacher, B. et a l . , manuscript 
submitted). For the TNF-specific ELISA, plates were coated with p u r i f i e d Vlq 
(10pq/ml). After incubation of the coated wells with s e r i a l dilutions of the test 
samples biotinylated protein A-purified polyclonal rabbit anti-rmTNF (Knoll AG, 
Ludwigshafen, FRG) Ig (ISpq/ml) was applied. The enzymatic a c t i v i t y after 
reaction with streptavidin-peroxidase and tetramethylbenzidine (Sigma) as 
peroxidase substrate was determined at 5 to 20 min. Se n s i t i v i t y of the ELISA was 
1 ng/ml for rmTNF. 
Interleukin 6 (IL61 Assay; The IL6 determination was performed using a 4 day 
pr o l i f e r a t i o n assay with the IL6-dependent hybridoma B9 (8). 
Immunohistochemistrv: Cell-associated TNF in tumor sections was determined with a 
protein A-purified rabbit anti-rmTNF Ig (Knoll AG, Ludwigshafen, FRG) and 
peroxidase-coupled goat anti-rabbit antibody (Dianova, Hamburg, FRG). As 
substrate 3-amino-9 ethylcarbazole (AEC, Sigma) was used. The presence of 
macrophages/monocytes was determined by staining of tumor sections with anti-Mac-
1 antibodies according to the supplier's protocol (Boehringer, Mannheim, FRG). 
RESULTS 
Mice received 106 CFS1 c e l l s intradermally and blood was drawn regularly 
during tumor growth beginning on day 6. No TNF was detectable i n the plasma of 
these tumor bearing animals at any time neither i n the TNF bioassay nor i n a TNF-
sp e c i f i c ELISA system. Even after an injection of bact e r i a l endotoxin 
(S.minneaota LPS, Sigma, lOpg/animal, ip) 2 hours before bleeding the mice, no 
TNF was found i n the plasma. Low levels of inter leukin 6 (IL6) were detectable i n 
the tumor-bearing animals from day 17 on after tumor implantation. In plasma of 
animals which had received bacterial endotoxin IL6 was always present, but the 
concentration did not change si g n i f i c a n t l y during tumor growth (data not shown). 
mRNA from the spleens of tumor-bearing mice was prepared and analyzed in 
Northern blo t s . The signal s p e c i f i c for TNFmRNA increased during tumor growth and 
was highest at the latest time point (day 24) of the experiment ( F i g . l ) . A peak 
of TNFmRNA on day 8 indicated a transient r i s e i n TNF expression i n the spleen 
during an early stage of tumor growth. 
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FIGURE 1: TNFmRNA Expression in Spleens of Tumor bearing Mice at Different Time 
Points after Tumor Implantation. The spleens of the mice were removed at the 
indicated times and TNFmRNA determined in Northern blot analysis. The TNFmRNA 
signal from spleens of non tumor bearing mice had a density of 6400. 
In situ hybridization of TNFmRNA in tumor tissue revealed very few TNF 
positive c e l l s at early stages of tumor growth. The number of c e l l s positive for 
TNFmRNA increased gradually from day 6 on (tested on days 6, 8, 10, 13, IS, 11, 
20, 22 and 24) and was maximal at the latest time point tested. Fig. 2 depicts 
t y p i c a l TNFmRNA signals in tumor tissue from day 8 and day 20 of tumor growth. 
Though subjective and d i f f i c u l t to quantify, this gradual increase of c e l l s 
showing TNFmRNA expression was highly reproducible in different sets of 
FIGURE 2: In Situ TNFmRNA Expression in Tumor Tissue. Tumor tissues from day 8 
(a) and day 20 (b) after tumor implantation were hybridized with a TNF-RNA probe. 
The photographs display the same tissue area x 250 as light and dark f i e l d 
photograph, respectively. 
hybridizations and tumor growth experiments. CFS1 tumor c e l l s themselves were 
negative for TNFmRNA expression and the c e l l s were not able to induce TNFmRNA 
expression i n murine peritoneal exudate macrophages in vitro. Immunhistochemical 
staining of the tumor sections with a polyclonal anti-rmTNF immunoglobulin 
fraction supported the results from in situ hybridizations showing similar 
numbers of TNF protein-containing c e l l s (data not shown). Staining of the tumor 
tissues for the presence of monocytes/macrophages also revealed an increasing 
number of Mac-1-positive c e l l s during tumor growth. The number of phagocytes 
detected by staining, however, exceeded the number of c e l l s with TNFmRNA signal 
considerably• 
After detection of tumor-induced endogenous TNF expression, we attempted to 
determine the role of thi s TNF for tumor growth. Therefore, the animals received 
an ip injection of murine TNF-neutralizing antibodies together with the tumor 
transplant and every t h i r d day thereafter. Fig* 3 shows the growth curves of the 
tumors i n untreated and anti-TNF-treated mice. No significant difference in the 
diameter of the tumors at any time became obvious. Also, the body weight of the 
animals on day 17 after tumor implantation did not vary between the two groups 
(15.6±1.3g for untreated versus 15.7±0.9g for anti-TNF-treated mice). Thus, 
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FIGURE 3: Tumor Growth i n Untreated and Anti-TNF-Treated Mice. In one group each 
animal received 100/¿g in 0.3ml Vlq hybridoma supernatant ip on the day of tumor 
implantation and every t h i r d day thereafter. Tumor diameters were measured i n the 
untreated group (O) and the anti-TNF-treated group (A) on the indicated days and 
are given with standard deviations. 
DISCUSSION 
The production of TNF during tumor growth in vivo as predicted by the 
li t e r a t u r e (1-5) was v e r i f i e d in the tumor model described above. Not only did 
tumor i n f i l t r a t i n g macrophages synthesize TNF but also c e l l s i n the spleens of 
these tumor bearing animals became positive for TNFmRNA. This indicated that 1. 
physical contact of tumor c e l l s with macrophages induced l o c a l production of TNF 
and 2. that the tumortransplant induced a status of inflammation leading to 
systemic activation of macrophages/monocytes. The high TNFmRNA expression in 
spleens after day 20 of tumor growth could also be based on the central necrosis 
in the tumors which was regularly observed at later stages of tumor growth. The 
fact that no plasma TNF was detected in the tumor-bearing animals i s i n agreement 
with a recent publication (7) but in contrast to the observed enhanced TNF levels 
in cancer patients (2,3). 
This could either be explained by the tumor type used for transplantation or by 
the s e n s i t i v i t y of the TNF assays used in these experiments. Detection of TNF in 
biol o g i c a l f l u i d s l i k e plasma i s sometimes d i f f i c u l t due to the high protein 
content of the test samples or due to the presence of inhibitors and/or soluble 
receptors. This could also be the reason for the fa i l u r e to detect TNF in the 
plasma of tumor bearing mice after endotoxin administration. This observation i s 
in contrast to non-tumor bearing mice where circulating TNF can regularly be 
found after endotoxin administration. The presence of IL6 at later stages of 
tumor growth might be an indirect sign of the presence of activated macrophages 
because TNF belongs to the best inducers for IL6 production (7). Tumor burden was 
shown to be a sensitizing factor for detrimental effects of TNF or endotoxin 
application (9). Therefore, the failure to detect any TNF release i n tumor-
bearing mice was rather unexpected. Although soluble TNF was not detected, TNF 
protein and TNFmRNA was clearly expressed in macrophages i n tumor tissue and 
TNFmRNA was expressed in spleen. 
In an attempt to c l a r i f y the role of this endogenously produced TNF during 
tumor growth, the mice were treated with neutralizing antibodies to murine TNF. 
The concentration of antibodies in the serum was high enough to completely 
neutralize endotoxin-induced TNF released in lethal shock situations 
(Echtenacher, B. et a l . , manuscript submitted) at any time of the experiment. 
This treatment, however, did not have any obvious effect in regard to the tumor 
growth or to the behavior of the animals. It i s conceivable that transplantation 
of such a large number of chemically induced tumor c e l l s simply overwhelms the 
primary defense system in which TNF i s meant to play a role as physiological 
mediator. A more simple explanation would be that the antibodies did not get to 
the relevant s i t e of TNF production and -action and, therefore, were ineffective. 
The elucidation of the role of endogenous TNF in tumor growth obviously needs to 
be investigated in more refined test systems. 
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